• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.

作者信息

Gourlet P, Vilardaga J P, De Neef P, Waelbroeck M, Vandermeers A, Robberecht P

机构信息

Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Belgium.

出版信息

Peptides. 1996;17(5):825-9. doi: 10.1016/0196-9781(96)00107-6.

DOI:10.1016/0196-9781(96)00107-6
PMID:8844773
Abstract

C-terminally truncated secretin and VIP molecules were synthesized, and their ability to occupy the recombinant secretin and VIP1 receptors stably expressed in Chinese hamster ovary (CHO) cells and to stimulate adenylate cyclase activity was studied. On secretin receptors, secretin (1-26) and secretin (1-24) were 10- and 50-fold less potent but as efficient as secretin (1-27); VIP (1-27) was as potent and efficient as VIP (1-28), and VIP (1-26) and VIP (1-25) were both 100-fold less potent. On VIP1 receptor, VIP (1-28) and VIP (1-27) were equipotent and VIP (1-26) and VIP (1-25) were 10- and 300-fold less potent, respectively; secretin (1-27) and secretin (1-26) were of equally low affinity and 10-fold more potent than secretin (1-24). Thus, the secretin and the VIP1 receptors had different selectivity profiles for the recognition of C-terminally truncated secretin and VIP derivatives. The chimeric receptors consisting in the N-terminal part of the secretin receptor on the core of the VIP1 receptor (N-Sn/VIP1.r) and in the N-terminal part of the VIP1 receptor on the core of the secretin receptor (N-VIP1/Sn.r) exhibited the selectivity pattern of the secretin and VIP1 receptors, respectively. The results suggest that the C-terminal end of secretin and VIP interacts with the N-terminal domain of the secretin and VIP receptors.

摘要

相似文献

1
The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
Peptides. 1996;17(5):825-9. doi: 10.1016/0196-9781(96)00107-6.
2
Interaction of amino acid residues at positions 8-15 of secretin with the N-terminal domain of the secretin receptor.促胰液素8-15位氨基酸残基与促胰液素受体N端结构域的相互作用。
Eur J Biochem. 1996 Jul 15;239(2):349-55. doi: 10.1111/j.1432-1033.1996.0349u.x.
3
Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.大鼠促胰液素受体的序列(103 - 110)和(116 - 120)与促胰液素和血管活性肠肽的识别有关。
Ann N Y Acad Sci. 2000;921:362-5. doi: 10.1111/j.1749-6632.2000.tb06994.x.
4
Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.在血管活性肠肽(VIP)、垂体腺苷酸环化酶激活肽(PACAP)和促胰液素中引入精氨酸16对配体与受体亲和力的影响。
Biochim Biophys Acta. 1996 Dec 12;1314(3):267-73. doi: 10.1016/s0167-4889(96)00106-1.
5
Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.
Biochem Biophys Res Commun. 1995 Jun 26;211(3):885-91. doi: 10.1006/bbrc.1995.1895.
6
Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.血管活性肠肽(VIP)、蛙皮素和垂体腺苷酸环化酶激活肽(PACAP)的类似物可区分大鼠和人类的VIP1和VIP2受体。
Ann N Y Acad Sci. 1998 Dec 11;865:247-52. doi: 10.1111/j.1749-6632.1998.tb11184.x.
7
Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
Ann N Y Acad Sci. 1998 Dec 11;865:386-9. doi: 10.1111/j.1749-6632.1998.tb11201.x.
8
Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.垂体腺苷酸环化酶激活多肽I和II受体、血管活性肠肽1以及嵌合氨基末端垂体腺苷酸环化酶激活多肽/血管活性肠肽1受体的特性:多种受体状态的证据
Mol Pharmacol. 1996 Dec;50(6):1596-604.
9
The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.血管活性肠肽(VIP)的C末端部分对于受体结合和激活很重要,这一点已通过VIP/促胰液素的嵌合构建体得到证实。
FEBS Lett. 1997 Aug 25;413(3):405-8. doi: 10.1016/s0014-5793(97)00942-3.
10
In vitro properties of a high affinity selective antagonist of the VIP1 receptor.血管活性肠肽1型受体高亲和力选择性拮抗剂的体外特性
Peptides. 1997;18(10):1555-60. doi: 10.1016/s0196-9781(97)00230-1.

引用本文的文献

1
Understanding VPAC receptor family peptide binding and selectivity.理解 VPAC 受体家族肽结合和选择性。
Nat Commun. 2022 Nov 16;13(1):7013. doi: 10.1038/s41467-022-34629-3.
2
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.(Pro3)GIP的种属特异性作用——它是人类GIP受体的完全激动剂,但在大鼠和小鼠GIP受体上是部分激动剂和竞争性拮抗剂。
Br J Pharmacol. 2016 Jan;173(1):27-38. doi: 10.1111/bph.13323. Epub 2015 Nov 20.
3
Secretin stimulates biliary cell proliferation by regulating expression of microRNA 125b and microRNA let7a in mice.
缩胆囊素通过调节小鼠 microRNA 125b 和 microRNA let7a 的表达来刺激胆汁细胞增殖。
Gastroenterology. 2014 Jun;146(7):1795-808.e12. doi: 10.1053/j.gastro.2014.02.030. Epub 2014 Feb 25.
4
Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.在胰高血糖素样肽-1(GLP-1)受体核心处进化上保守的残基赋予配体诱导的受体激活。
J Biol Chem. 2012 Feb 3;287(6):3873-84. doi: 10.1074/jbc.M111.276808. Epub 2011 Nov 21.
5
Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.内酰胺限制提供了关于分泌素受体结合构象的见解,并稳定了受体拮抗剂。
Biochemistry. 2011 Sep 27;50(38):8181-92. doi: 10.1021/bi2008036. Epub 2011 Aug 30.
6
Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.使用中区域光亲和探针和分子建模对胰高血糖素样肽 1 与其完整受体的对接进行精细化研究。
J Biol Chem. 2011 May 6;286(18):15895-907. doi: 10.1074/jbc.M110.217901. Epub 2011 Mar 16.
7
Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.胰高血糖素受体 N 端结构域的突变和半胱氨酸扫描分析。
J Biol Chem. 2010 Oct 1;285(40):30951-8. doi: 10.1074/jbc.M110.102814. Epub 2010 Jul 20.
8
Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.胰高血糖素样肽 1 及其受体氨基末端区域 6 至 12 位残基之间的空间近似:一个对生物活性至关重要的区域。
J Biol Chem. 2010 Aug 6;285(32):24508-18. doi: 10.1074/jbc.M110.135749. Epub 2010 Jun 7.
9
Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment.缩胆囊素占据同二聚体缩胆囊素受体复合物的单个单体:来自使用共价连接的双重位点的光亲和标记研究的见解。
J Biol Chem. 2010 Mar 26;285(13):9919-9931. doi: 10.1074/jbc.M109.089730. Epub 2010 Jan 25.
10
Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes.用羧基末端光不稳定探针研究胰高血糖素样肽1与其完整受体对接的分子基础。
J Biol Chem. 2009 Dec 4;284(49):34135-44. doi: 10.1074/jbc.M109.038109. Epub 2009 Oct 8.